Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986094 and Daclatasvir in Chronic HCV
NCT01629732Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986094 in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Planned start Mar 2013; status: withdrawn.
02
Drugs
BMS-986094
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01629732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01629732.